Skip to Main content Skip to Navigation
Journal articles

Optimization of biologics to reduce treatment failure in inflammatory bowel diseases

Abstract : Moderate to severe inflammatory bowel disease patients can fail to respond to conventional therapy and/or to biologic treatment. In the era of TNFα antagonists and other non-anti-TNF biologic drugs, it is important to review the literature on biologic treatment failure, which could be defined as primary non-response, secondary loss of response and intolerance. Therapeutic drug monitoring (TDM), that is, drug trough level and antidrug antibodies, should enable to determine the mechanisms of treatment failure and to optimize drug efficacy. There is a consensus on reactive TDM at the time of loss of response. Proactive TDM could be of interest during induction and/or maintenance, but randomized controlled trials are required.
Document type :
Journal articles
Complete list of metadata

https://hal.inrae.fr/hal-02983219
Contributor : Nathalie Seguin <>
Submitted on : Thursday, October 29, 2020 - 2:55:25 PM
Last modification on : Friday, June 4, 2021 - 2:40:21 PM

Identifiers

Collections

Citation

Aurélie Bourchany, Cyrielle Gilletta de Saint-Joseph, Anne Breton, Frédérick Barreau, Emmanuel Mas. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Current Opinion in Pharmacology, Elsevier, 2020, 54, pp.51-58. ⟨10.1016/j.coph.2020.07.012⟩. ⟨hal-02983219⟩

Share

Metrics

Record views

24